#ASH16: Pfizer offers a thumbs-up on OS data from PhII blood cancer study of glasdegib
Pfizer came up with some solidly positive Phase II data for a new drug that’s designed to throw a monkey wrench into the biology driving the hedgehog pathway in acute myeloid leukemia.
Investigators said that glasdegib, an oral SMO inhibitor initially coded PF-04449913, significantly increased the overall survival of a group of patients taking the drug in combination with low-dose cytarabine (LDAC) compared to LDAC alone.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters